08.00 REGISTRATION & COFFEE 08.30 Opening Speech: “The Promise and Threat of Precision Cancer Medicine” by: Barrett J. Rollins, MD, PhD Linde Family Professor of Medicine at Harvard Medical School, Chief Scientific Officer at Dana-Farber Cancer Institute 08.55 Deal Making Co-Chaired by: Anne Altmeyer, VP, BD & Licensing, Head Negotiation, Oncology, Novartis Pharmaceuticals Dov Hass, Associate, Morgan, Lewis & Bockius LLP Panellists: Dennis Purcell, Founder and Senior Advisor, Aisling Capital LLC Francis Kern, Senior Director of External Scientific Affairs, Daiichi Sankyo Catherine Pickering, Head of Oncology Licensing, Global BD, Merck Serono Pharmaceuticals Howard J. Fingert, Senior Medical Director, BD & Clinical Intelligence, Takeda, Inc. Ji Li, Vice President, Business Development and Licensing, Merck Research Laboratories 09.55 10.55 NextGen Immunotherapeutics Co-Chaired by Mara Goldstein, Managing Director & Senior Biotechnology Analyst, Cantor Fitzgerald Raffaele Baffa, Senior Director, Translational and Experimental Medicine, Sanofi Aventis Panellists: Dragan Cicic, COO and CMO, Actinium Pharmaceuticals, Inc. Gil Beyen, Chairman and CEO, ERYTECH Pharma SA Greg Naeve, Head of Strategic Research Partnerships, Oncology, Pfizer Jeff Abbey, President and CEO, Argos Therapeutics, Inc. Marc Mansour, CEO, Immunovaccine, Inc. Paul Higham, Managing Director and CEO, immatics biotechnologies GmbH Robert de Petit, Chief Scientific Officer, Advaxis, Inc. COFFEE BREAK Emerging Presenting Companies Track 09.05 Pelican Therapeutics 09.15 Rexahn Pharmaceuticals, Inc. 09.25 SolaranRx, Inc. 09.35 Microbial Robotics 09.45 BBS Nanotechnologies 09.55 TBA 10.05 NYU Office of Therapeutics Alliances 10.15 TBA 10.25 TBA 10.35 TBA Presenting Companies TRACK A 11.10 12.10 13.00 Gene & Cell Therapy Co-Chaired by: Maxim Jacobs, Senior Healthcare Analyst, Edison Group Mike Rice, Senior Consultant, Defined Health Panellists: Madhusudan Peshwa, Executive Vice President, Cellular Therapies, MaxCyte, Inc. Robert Dillman, Vice-President, Oncology, NeoStem, Inc. Peter Hoang, Senior Vice President BD & Strategy, Bellicum Pharmaceuticals Peter Sandor, Vice President, Global Marketing Oncology TA, Amgen, Inc. Personalized Medicine & Diagnostics Co-Chaired by: Stephen Brozak, Managing Partner and President, WBB Securities, LLC Rowan Chapman, Managing Director, Ventures, GE Healthcare Panellists: Bernhard Sixt, President and CEO, ImmunID Claudio Carini, Global Clinical Immunology and Biomarkers Lead, Pfizer Lisa Ricciardi, SVP, Corporate & Business Development, Foundation Medicine, Inc. Thomas Tulip, Executive Vice President and CBO, Navidea Biopharmaceuticals 11.00 Berg LLC 11.15 BerGenBio AS 11.30 Nanobiotix SA 11.45 IMMUNE Pharmaceuticals 12.00 Enumeral Biomedical Holdings, Inc. 12.15 XEME Biopharma, Inc. 12.30 TapImmune, Inc. NETWORKING LUNCH Presenting Companies TRACK B Presenting Companies TRACK C 14.00 Advaxis, Inc. Actinium Pharmaceuticals 14.15 Argos Therapeutics, Inc. CASI Pharmaceuticals, Inc. 14.30 ERYTECH Pharma SA MaxCyte, Inc. 14.45 Immunovaccine, Inc. Novogen Ltd. 15.00 Navidea Biopharmaceuticals immatics biotechnologies GmbH 15.15 NeoStem, Inc. Cell Source Ltd. 15.30 CEL-SCI CORPORATION ImmunID 15.45 COFFEE BREAK 16.00 Public & Private Partnerships Co-Chaired by: Lee Greenberger, Chief Scientific Officer, The Leukemia and Lymphoma Society O. Prem Das, Chief Business Development Officer, Dana-Farber Cancer Institute Panellists: Daniel Auclair, Vice President, Translational Research, The Multiple Myeloma Research Foundation Darryl Mitteldorf, Executive Director, Global Prostate Cancer Alliance Juan Carlos Lopez, Head of Academic Relations & Collaborations, Roche Leigh Zawel, Site Head, New York and Boston Centers for Therapeutic Innovation, Pfizer, Inc. Louise Perkins, Chief Science Officer, Melanoma Research Alliance Steven Young, President & COO, Addario Lung Cancer Medical Institute 17.00 Investment Roundtable Co-Chaired by: Beth Jacobs, Managing Partner, Excellentia Global Partners Stuart Barich, Managing Director, Raymond James Financial, Inc. Panellists: Daniel Teper, CEO, IMMUNE Pharmaceuticals Jens Eckstein, President, SR ONE Philippe Muaberna, CFO, Nanobiotix SA Shakti Narayan, Sr. Director, Transactions, Johnson & Johnson Todd Foley, Managing Director, MPM Capital LLC 18.00 NETWORKING RECEPTION 19.00 END OF THE FORUM